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ABSTRACT:
Azacitidine is the leading compound to treat patients suffering myelodysplastic 
syndrome (MDS) or AML with less than 30% of blasts, but a majority of patients 
is primary refractory or rapidly relapses under treatment. These patients have a 
drastically reduced life expectancy as compared to sensitive patients. Therefore 
identifying predictive factors for AZA resistance is of great interest to propose 
alternative therapeutic strategies for non-responsive patients. We generated 
AZA-resistant myeloid cell line (SKM1-R) that exhibited increased expression of 
BCL2L10 an anti-apoptotic Bcl-2 family member. Importantly, BCL2L10 knockdown 
sensitized SKM1-R cells to AZA effect suggesting that increased BCL2L10 expression 
is linked to AZA resistance in SKM1-R. We next established in 77 MDS patients that 
resistance to AZA is significantly correlated with the percentage of MDS or AML 
cells expressing BCL2L10. In addition, we showed that the proportion of BCL2L10 
positive bone marrow cells can predict overall survival in MDS or AML patients. We 
propose a convenient assay in which the percentage of BCL2L10 expressing cells 
as assessed by flow cytometry is predictive of whether or not a patient will become 
resistant to AZA. Therefore, systematic determination of BCL2L10 expression 
could be of great interest in newly diagnosed and AZA-treated MDS patients.
INTRODUCTION
Azacitidine (AZA) is a hypomethylating agent 
approved for the treatment of patients suffering 
myelodysplastic syndromes[1] (MDS) and acute 
myeloid leukemia (AML) with low (20–30%) bone 
marrow blast counts in USA, Europe and other countries 
yielding 40–60% response in this disease[2, 3]. 
Current prognostic scoring systems consider karyotype 
abnormalities and certain clinical features to stratify 
patients with MDS into risk groups[4]. Thus, update of 
prognostic scoring is mainly based on new cytogenetic 
subgroups[5]. Cytogenetic findings can predict and are 
prognostic for overall survival (OS) in patients treated 
with hypomethylating agents[6, 7] but are relatively 
poor predictors of response[8]. Half of patients with 
MDS exhibit a normal karyotype, and patients with 
identical chromosomal abnormalities are often clinically Oncotarget 2012; 3:  490-501 491 www.impactjournals.com/oncotarget
heterogeneous[5, 9]. Somatic point mutations are 
common in MDS. Mutations in TP53,  EZH2,  ETV6, 
RUNX1, DNMT3A and ASXL1 are predictors of poor OS 
in patients with MDS independently of other established 
risk factors[9-11]. Genetic alterations of the major splicing 
components including SF3B1 have been also reported in 
MDS[12-14]. However, prognostic impact depending on 
the treatment of all these mutations was not evaluated in 
this cohort of patients. To date, only mutations in TET2 
have been identified as genetic predictors of response to 
AZA[15]. 
MDS or AML patients treated with AZA are 
either primary refractory (AZA-resistant) or AZA-
sensitive but systematically relapse upon treatment with 
various time lapses[2]. Globally, only 17% of complete 
remission is observed with AZA treatment. Presence of 
partial remission and stable disease with hematologic 
improvement showed an increasing of OS in MDS or AML 
patients treated by AZA. Therefore, relapse or refractory 
patients are defined by presence of progression or stable 
disease without hematologic improvement according to 
IWG 2006 criteria. Outcome of MDS patient after AZA 
treatment failure is poor with a median overall survival 
of 5.6 months[16]. Importantly, no consensus genetic 
predictor of response to AZA or relapse after initial AZA 
sensitivity has been reported so far. Therefore, it seems 
of great importance to identify as early as possible those 
MDS patients treated by hypomethylating agents that will 
relapse inexorably in order to propose other clinical trials 
before worsening of clinical conditions.
We recently generated AZA-resistant SKM1 myeloid 
cells following long-term incubation with increasing 
concentrations of AZA. These cells exhibited impaired 
apoptosis in response to AZA[17]. In the present study, 
taking opportunity of the availability of this cell line 
model, we identify a new potential prognostic factor for 
the response to AZA in MDS. Indeed, we show for the 
first time that protein expression of BCL2L10, an anti-
apoptotic member of the Bcl2 family is increased and 
correlated with AZA resistance in the AZA-resistant 
SKM1  cell line and that the percentage of BCL2L10 
positive cells MDS primary sample patients can predict 
AZA resistance. We propose that systematic determination 
of the percentage of BCL2L10 positive cells by flow 
cytometry could be of great interest before treating MDS 
or AML patients with AZA. Moreover, evaluation of an 
increase in the proportion of BCL2L10 positive MDS cells 
could be also interesting in the course of AZA treatment. 
RESULTS
Validation of a flow cytometry-based assay for 
BCL2L10 detection
We recently generated AZA-resistant SKM1 cells 
(SKM1-R) defective for AZA-induced apoptosis[17]. 
Compared to their AZA-sensitive counterpart SKM1-R 
cells exhibited increased protein expression of BCL2L10 
(Bcl-B), an anti-apoptotic member of the Bcl-2 family 
but equivalent levels of Bcl-2, Bcl-xL and Mcl-1 proteins 
(Figure 1). Increased BCL2L10 protein expression was 
also found in the SKM1-R bulk before limited dilution 
Bcl-2
Bcl-xl
Mcl-1
BCL2L10
- +         - +
SKM1-S SKM1-R
HSP60
Blot: AZA 
Figure 1: Expression of anti-apoptotic Bcl2 family members in SKM1-sensitive and resistant cell lines. SKM1-S and 
SKM1-R were treated for 24h with 1µM AZA and Western Blots were carried out to assess Bcl-2, Mcl-1, Bcl-xL and BCL2L10 protein 
expression. HSP60 was used as loading control. Oncotarget 2012; 3:  490-501 492 www.impactjournals.com/oncotarget
and also in another SKM1-R subclone (not shown), 
indicating that overexpression of BCL2L10 is linked 
to AZA resistance and is not due to a clonal effect. To 
analyze BCL2L10 protein expression, we developed a 
cytometry-based assay in HEK293 cells. HEK293 cells 
were first transfected with a tagged-Myc construct as a 
negative control or a tagged-Myc-BCL2L10 construct 
and transfection efficiency was assessed using an anti-
BCL2L10 antibody. Endogenous BCL2L10 protein was 
detected in HEK293 cells transfected with the tagged-
Myc construct (Figure S1A, curve 2) whereas a stronger 
staining was visualized in HEK293 cells overexpressing 
BCL2L10 as expected (Figure S1A, curve 3). BCL2L10 
protein overexpression was confirmed by western blot 
Figure 2: BCL2L10 protein expression in SKM1-S and SKM1-R cell lines. (A) BCL2L10 protein level was quantified by flow 
cytometry in SKM1-S and SKM1-R cells as described in Supplementary Figure 1. (B) RT-PCR analysis of BCL2L10 mRNA expression in 
SKM1-S and SKM1-R cells. (C) BCL2L10 protein level was vizualized by Western Blot in SKM1-S and SKM1-R cells.Oncotarget 2012; 3:  490-501 493 www.impactjournals.com/oncotarget
using an anti-BCL2L10 mAb (Figure S1B). To validate the 
flow cytometry assay, we next used a specific BCL2L10 
siRNA to knockdown BCL2L10 expression in HEK293 
cells (Figure S1C). In this condition and conversely to the 
situation in which a control Luc siRNA was used (Figure 
S1C, curve 1), neither BCL2L10 protein expression nor 
BCL2L10  staining  were  detected  by  flow  cytometry 
(Figure S1C, curve 2) and western blot (Figure S1D) 
Figure 3: BCL2L10 knockdown sensitizes SKM1-R to the effect of AZA. SKM1-S and SKM1-R cells were transfected with 
either control Luc, BCL2L10 or a Bcl-2 siRNAs. 72h after transfection, cells were stimulated with 1µM AZA. (A) Cell metabolism was 
assessed 24h later using the XTT assay as described in the material and methods section. Results represent the mean ± SEM of three 
independent experiments made in quadruplicates. Active caspase 3 (B) and propidium iodide staining (C) were visualized by flow cytometry 
24h after the addition of 1µM AZA. (D) Western Blots were also carried out at the same time to assess BCL2L10 and Bcl-2 expression.Oncotarget 2012; 3:  490-501 494 www.impactjournals.com/oncotarget
validating our flow cytometry-based assay for BCL2L10 
detection. 
Overexpression of BCL2L10 participates to AZA 
resistance in SKM1 cells
Using the same assay, we established that 
significantly more SKM1-R cells expressed BCL2L10 
protein compared to SKM1-S (73% versus 39%) and that 
globally BCL2L10 expression was increased in SKM1-R 
cells (Figure 2A). An increased expression of both 
BCL2L10 mRNA and protein levels was also detected 
in SKM1-R cells as judged by RT-PCR (Figure 2B) and 
western blot (Figure 2C). 
To determine whether BCL2L10 overexpression 
is the cause rather than a consequence of resistance to 
AZA, SKM1-S and SKM1-R cells were transfected 
with either a control siRNA or a siRNA directed against 
BCL2L10 and next treated for 24 h with or without AZA, 
before determination of cell viability and apoptosis. AZA 
triggered a loss of cell metabolism in SKM1-S but not 
in SKM1-R cells (Figure 3A), as expected. Knockdown 
of BCL2L10 restored sensitivity to AZA in SKM1-R 
suggesting an important role for BCL2L10 in resistance 
Figure 4: BCL2L10 protein expression is increased in AZA-resistant patients. BCL2L10, Bcl-2 and ERK expression was 
analyzed by Western Blot on fresh bone marrow samples prepared from 7 healthy subjects, 7 AZA-sensitive and 5 AZA-resistant patients. 
(A) A Western Blot is shown for two representative patients of each subgroup. (B and C) BCL2L10, Bcl-2 and ERK quantification was 
performed using the Image J software and the ratio of BCL2L10 or Bcl-2 versus ERK expression were quantified. Oncotarget 2012; 3:  490-501 495 www.impactjournals.com/oncotarget
to AZA. For an unknown reason cell metabolism was 
higher in SKM1-S and SKM1-R cells treated with the 
BCL2L10 siRNA (Figure 3A). In addition, apoptosis was 
the main mechanism by which BCL2L10 knockdown 
mediated sensitization to AZA since both an increase in 
active caspase 3 and PI positive cells were detected in 
SKM1-R treated with a BCL2L10 siRNA (Figure 3B 
and C). This effect was specific for BCL2L10 because a 
siRNA directed against Bcl-2 failed to do so in identical 
conditions (Figure 3B and C). Of note, it should be pointed 
out that SKM1-R had higher active caspase 3 levels than 
their SKM1-S counterpart (Figure 3B and C). Finally we 
checked by western blotting that both siRNAs were able 
to abolish expression of their respective targets (Figure 
3D). Collectively, our findings established that BCL2L10 
protein overexpression is responsible for AZA resistance 
in SKM1-R cells.
Figure 5: AZA-R MDS or AML patients treated with AZA have increased percentage of BCL2L10 expressing cells in 
their bone marrow. (A) The percentage of BCL2L10 positive cells was quantified by flow cytometry in 32 MDS or AML patients treated 
with AZA and in 8 healthy subjects (cohort 1). (B) The percentage of BCL2L10 positive cells was quantified by flow cytometry in DMSO-
frozen samples from 14 low-risk MDS patients, 31 high-risk MDS or AML patients treated with AZA (cohort 2). (C) Subgroups analysis of 
patients from cohort 2 was also performed (Figure 5B). The percentage of BCL2L10 positive cells was quantified in DMSO-frozen samples 
from 16 MDS high-risk patients or AML patients at diagnosis (left panel) and in DMSO-frozen samples from 15 MDS high-risk or AML 
patients under AZA treatment (right panel).Oncotarget 2012; 3:  490-501 496 www.impactjournals.com/oncotarget
BCL2L10 expression is predictive of resistance to 
AZA in MDS patients
We also analyzed BCL2L10 expression by western 
blot on patient samples, when sufficient material was 
available. Results presented on Figure 4 revealed that the 
level of BCL2L10 tends to be higher in two representative 
AZA-resistant patients as compared to two representative 
AZA-sensitive or healthy patients (Figure 4A). Using 
ERK protein as an internal control for each patient sample, 
we showed that BCL2L10 versus ERK protein expression 
was drastically higher in 5 AZA-resistant versus 7 AZA-
sensitive patients, whereas the level of BCL2L10 versus 
ERK protein expression was very low in 7 healthy subjects 
(Figure 4B). Conversely, Bcl-2 protein expression was 
not significantly different in the three groups of patients 
(Figure 4C). Collectively, these results suggest that 
BCL2L10 expression is predictive of AZA-resistance in 
MDS patients.
BCL2L10 protein expression as a biomarker of 
AZA resistance in MDS patients
We next determined the percentage of BCL2L10 
positive cells in freshly isolated bone marrow (BM) 
samples from 8 healthy subjects, 24 AZA-sensitive 
patients and 8 AZA-resistant patients (Cohort 1, fresh 
samples) using our cytometry-based assay. The clinical 
features of all patients are given in supplemental Table S1 
and S2. As shown on Figure 5A the mean values for freshly 
isolated BM samples from healthy subjects and AZA-
sensitive patients were respectively 0% (0-18) and 8% 
(0-40) BCL2L10 positive cells, whereas the mean value 
for BM cells from AZA-resistant patients was 85% (57-
99) BCL2L10 positive cells (p<0.0001) (Figure 5A). In 
a second cohort (cohort 2 / frozen samples), retrospective 
comparison of BM samples from low risk MDS patients 
(n=14), AZA-sensitive (n=21) or AZA-resistant patients 
(n=10) showed that the counts of BCL2L10 positive 
cells of low risk MDS patients was 0% (0-11), whereas 
AZA-resistant patients had significantly higher numbers 
of BCL2L10 positive cells as compared to AZA-sensitive 
patients (33% versus 10%, p<0.0001) (Figure 5B).
In addition, we performed subgroups analysis from 
the 21 AZA-sensitive patients and the 10 AZA-resistant 
patients from cohort 2 (Figure 5B). AZA-primary resistant 
patients (n=6) had significantly higher counts of BCL2L10 
positive cells (29%) than AZA-sensitive patients at 
diagnosis (10%) (n=6) (Figure 5C, left panel) (p=0.023). 
AZA-sensitive patients at relapse (n=4) exhibited high 
counts of BCL2L10 positive cells (43%), as compared 
to AZA-sensitive patients (n=11) under treatment (14%) 
(Figure 5C, right panel) (p=0.0002). 
Finally, we analyzed in two patients (#4) and 
(#23), the parallel evolution of bone marrow blast counts 
and the percentage of BCL2L10 positive cells. After 9 
cycles of AZA, patient #23 was sensitive to AZA, had 
12%  blasts  (RAEB-II  in  the  MDS  classification)  and 
40% BCL2L10 positive cells (Figure S2A). This patient 
remains sensitive after 12 and 15 cycles of AZA. When 
this patient became resistant after 18 cycles of AZA, its 
blast counts and BCL2L10 positivity increased to 35% and 
90%, respectively. These results suggest that BCL2L10 
expression is a hallmark of resistance to AZA. In contrast, 
patient #4 who remained sensitive to AZA all along the 
treatment (over 29 cycles), failed to exhibit any increase 
in blast counts and in the number of BCL2L10 positive 
cells (Figure S2B).
The percentage of BCL2L10 positive cells predicts 
OS in MDS and AML patients
We established that a cut-off of 50% BCL2L10 
positive cells discriminates well between AZA-sensitive 
and resistant patients. Using this cut-off and the patients 
from cohort 1, we established that the test had excellent 
positive and negative predictive values. Globally, the 
test sensitivity and specificity was 80% and 85%. With a 
median follow-up of 4 months (range, 0.1 to 7.5 months) 
from  the  date  of  quantification  of  BCL2L10  positive 
cells, OS was significantly better in patients of cohort 
1 exhibiting low percentage of BCL2L10 positive cells 
versus patients exhibiting high percentage of BCL2L10 
positive (p=0.0016) (Figure 6). Estimated 3-month OS 
was 95% versus 51% in the subgroup of patients with low 
percentage of BCL2L10 positive cells compared to the 
subgroup of patients with high percentage of BCL2L10 
positive cells, respectively. Importantly, all patients with 
a high percentage of BCL2L10 positive cells progressed 
rapidly. Among them four died and two others were treated 
with intensive chemotherapy followed by allogeneic 
stem cell transplantation. In the subgroup of patients 
exhibiting low percentage of BCL2L10 positive cells, one 
patient died of sepsis, and all others patients remained 
AZA sensitive according to the IWG 2006 or AML2003 
criteria. Among these patients, 7 had a stable disease with 
hematologic improvement, 5 had a partial response and 
11 patients had a complete response. The relative risk of 
this test using a cutoff of 50% BCL2L10 positive cells was 
estimated 11.5.
DISCUSSION
BCL2L10 is a member of the Bcl-2 family that 
exhibits potent anti-apoptotic activity in vitro. Accordingly, 
BCL2L10 shares with the Bcl-2 protein family the well-
conserved BH4, BH1 and BH2 domains and lack the BH3 
domain that is characteristic of pro-apoptotic members 
of the Bcl2 family[25, 26]. BCL2L10 can interact with 
other members of the Bcl-2 family including Bcl-2, Bcl-Oncotarget 2012; 3:  490-501 497 www.impactjournals.com/oncotarget
xL and Bax to regulate apoptosis in different contexts[25, 
27, 28]. Accordingly to its anti-apoptotic function, 
overexpression of BCL2L10 has been reported to suppress 
apoptosis through inhibition of cytochrome C release from 
mitochondria[26].
In a recent report, Fabiani et al reported that 
Decitabine another hypomethylating agent triggers 
apoptosis and up-regulation of several genes including 
BCL2L10[29]. Moreover, in primary samples from 
patients they found that BCL2L10 promoter was 
methylated in approximatively one-half AML and related 
myeloid neoplasms, 13% of MDS samples and in none 
of the controls. In a more recent report the same group 
showed that a higher methylation rate of BCL2L10 was 
significantly associated to worse OS in patients enrolled 
into the GIMEMA MDS0205 multicenter trial. This was 
confirmed in a group of 27 HR-MDS patients, treated with 
AZA. Patients with high BCL2L10 promoter methylation 
status had also a lower probability of achieving complete 
responses. However, in both study the authors did not 
study the relation between methylation of the BCL2L10 
promoter and modulation of expression of its mRNA 
or protein level[30]. Of note, in gastric cancer cells 
methylation of the BCL2L10 promoter seems to correlate 
with decreased expression of BCL2L10 protein level 
[31, 32].  Taking into account the discrepancies reported 
regarding the impact of BCL2L10 promoter methylation 
status, it appears of great interest to consider its protein 
rather than its mRNA expression, in agreement with a 
recent report by Beverly et al. [33].
When we looked for BCL2L10 protein expression 
either by Western Blot or using our cytometry-based assay, 
expression of BCL2L10 was correlated with resistance 
to AZA in vitro. Importantly, knockdown of BCL2L10 
but not Bcl2 by specific siRNA sensitized SKM1-R to 
AZA-mediated apoptosis clearly demonstrating an anti-
apoptotic role for BCL2L10 in our cellular model. This 
was expected taking into account the structural homology 
of BCL2L10 with anti-apoptotic members of the Bcl2 
family and the known anti-apoptotic function of this 
protein. Our results are in very good agreement with two 
studies in the literature that linked resistance of cancer cell 
lines established from solid tumor and myeloid leukemia 
to various chemotherapeutic agents and overexpression of 
BCL2L10 both at the mRNA and protein level [34, 35]. 
In addition, it has been recently reported that BCL2L10 
expression was increased in patients with Multiple 
Myeloma (MM)[36]. In MM, BCL2L10 overexpression 
is clearly associated with apoptosis inhibition since 
BCL2L10  knockdown  by  specific  siRNA  or  targeting 
BCL2L10 function by a small peptidomimetic consistently 
increased cell death[19], in good agreement with our own 
findings.
Importantly, we also establish in the present study 
that the number of BCL2L10 positive cells in the bone 
marrow is predictive of AZA resistance. Moreover, the 
Figure 6: Correlation between the percentage of BCL2L10 expressing cells and OS in MDS or AML patients treated 
with AZA. Kaplan-Meier OS curves of AZA-treated MDS or AML patients with more or less than 50% BCL2L10 expressing cells in their 
bone marrow. ‡ indicate allografted patientsOncotarget 2012; 3:  490-501 498 www.impactjournals.com/oncotarget
percentage of BCL2L10 expressing BM cells from either 
healthy subjects or low-risk MDS patients was very low, 
conversely to the one of AZA-R patients. We confirmed by 
Western Blot that increased expression of BCL2L10 was a 
hallmark of AZA-resistant patients even though BCL2L10 
expression and BCL2L10 positive cell counts were 
variable from one resistant patient to another. Collectively, 
our findings are consistent with an anti-apoptotic role of 
BCL2L10 in MDS that impacts on the sensitivity to AZA. 
In this line, over-expression of BCL2L10 positive cells not 
only correlates with resistance to AZA in vitro but is also 
a predictive factor for resistance to AZA in MDS patients.
Finally, we also established using Kaplan-Meier 
representation that OS of patients with less than 50% 
of BCL2L10 positive cells in the bone marrow was 
significantly  higher  than  that  of  patients  with  more 
than 50% BCL2L10 positive cells. This test was highly 
sensitive and highly predictive for the outcome of patients. 
Finally, we found that all patients who were initially 
sensitive to AZA had lower level of BCL2L10 positive 
cells in their BM but consistently increased this number 
when they became resistant to this treatment.
In conclusion, we propose a very convenient and 
simple  flow  cytometry-based  assay  to  systematically 
quantify BCL2L10 positive cells in the bone marrow of 
MDS or AML patients either at diagnosis or during the 
normal course of the disease. Patients with more than 50% 
BCL2L10 positive cells in the bone marrow at diagnosis 
could be considered as not eligible for AZA treatment. 
In these patients alternative therapy targeting BCL2L10 
should be proposed. In this regard, peptidomimetics 
including Gossypol, ApoG and antimycin A which are 
potent inhibitor of BCL2L10 should be tested.
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MATERIALS AND METHODS
Reagents and antibodies
RPMI, DMEM and fetal calf serum (FCS) were 
purchased from Invitrogen (Villebon sur Yvette, 
France).  Sodium  fluoride,  sodium  orthovanadate, 
phenylmethylsulfonyl  fluoride  (PMSF),  aprotinin, 
leupeptin, 5-Azacitidine were purchased from Sigma 
(Saint-Louis, MO, USA). Anti-BCL2L10, anti-Bcl-
xL, anti-ERK and anti-rabbit antibodies were from 
Cell Signaling Technology (Beverly, MA, USA). Anti-
Bcl-2, Peroxidase-conjugated anti-goat and Peroxidase-
conjugated anti-mouse antibodies were from Dakopatts 
(Glostrup, Denmark). HSP-60 and Mcl-1 antibodies were 
from Santa Cruz Biotechnology (Heidelberg, Germany). 
Alexa Fluor 488 Donkey anti-rabbit antibody was from 
Invitrogen (Villebon sur Yvette, France). 
Cell lines
The human cell lines SKM1-S and SKM1-R have 
been described elsewhere[17] and were cultured in RPMI 
1640 supplemented with 10% FCS, 50 U/ml penicillin, 50 
mg/ml streptomycin, and 1mM pyruvate under 5% CO2 in 
a humidified incubator. The Kidney cell line HEK293 was 
cultured in DMEM supplemented with 10% FCS, 50 U/
ml penicillin, 50 mg/ml streptomycin, and 1mM pyruvate 
under 5% CO2 in a humidified incubator. 
Quantification of BCL2L10 by flow cytometry
White blood cells from bone marrow samples were 
isolated by density centrifugation (Ficoll-Paque Plus). 
Cells were fixed by paraformaldehyde 3%, permeabilized 
with Triton 0,1% and incubated with an anti-BCL2L10 
antibody. Cells were incubated with secondary donkey 
anti-Rabbit FITC-antibody. BCL2L10 protein expression 
was quantified by flow cytometry (FL2 channel).
RNA  isolation  and  Reverse  Transcription 
Polymerase Chain Reaction (RT-PCR)
Isolation of RNA and RT–PCR has been described 
in detail elsewhere[18]. To confirm differential mRNA 
expression, BCL2L10 mRNA was quantified by RT–PCR 
using the following primers: Forward primer (5’-3’) was 
CCT-TCA-TTT-ATC-TCT-GGA-CAC-G and Reverse 
primer (5’-3’) was TTT-CAC-TCA-AGG-AAG-AGC-C. 
PCR products (30µl) were loaded onto 3% agarose gels Oncotarget 2012; 3:  490-501 499 www.impactjournals.com/oncotarget
and visualized under ultraviolet light after staining with 
ethidium bromide.
Plasmid constructions and directed mutagenesis
Epitop tagged-pEGFP expression and tagged-Myc 
pcDNA3-BCL2L10 plasmids have been previously 
described[19]. HEK293 cells were transfected with 
plasmid using JetPEI (Polyplus Transfection, Brighton, 
UK) according manufacturer’s procedure.
Western blot analysis
After stimulation with various effectors for 24 
h, cells were harvested and lysed in buffer containing 
1% Triton X-100 and supplemented with protease and 
phosphatase inhibitors (Roche Diagnostics). Lysates were 
pelleted, and 50 μg of protein were analyzed by SDS-
PAGE. Blot quantification was performed with Image J 
Software.
RNA interference
The si-RNAs used for BCL2L10 and Bcl-2 
knockdown have been described previously[19]. Briefly, 
cells were transfected with a si-RNA directed against 
either BCL2L10, Bcl-2, or Luciferase (Invitrogen, 
Villebon sur Yvette, France) (50 nM) using an Amaxa 
nucleofector for SKM1 cell lines or using Lipofectamine 
RNAiMAX (Invitrogen, Villebon sur Yvette, France) for 
HEK293 cell line. Seventy-two hours after transfection 
AZA-S and AZA-R cells were treated with 1 μM AZA 
for 24h. BCL2L10 and Bcl-2 expression were analyzed 
by protein gel blot. 
Assessment of cell metabolism
Cell metabolism was determined with XTT 
assay[20]. Cells (20 x 103 cells) were incubated in a 96-
well plate for 24h with AZA 1µM at a final volume of 100 
μl. After 24h, 50 μl of XTT reagent was added to each 
well. The absorbance of the formazan product, reflecting 
cell metabolism, was measured at 490 nm. Each assay was 
performed in quadruplicate.
Propidium iodide (PI) staining
After stimulation with 1µM AZA for 24h, cells were 
washed with PBS and stained with propidium iodide. 
Fluorescence was measured using the FL3 channel of a 
fluorescent-activated cell sorter (Miltenyi cytometer)[21].
Active caspase 3 staining
After stimulation with 1µM AZA for 24h, cells were 
washed and stained with an anti-active caspase 3 antibody. 
Fluorescence was measured using the FL2 channel of a 
fluorescent-activated cell sorter (Miltenyi cytometer)[22].
Patients Samples
Two cohorts of patients were used for this study. In 
Cohort 1, fresh bone marrow samples were collected from 
32 patients treated with AZA. All patients had diagnosis 
of MDS or AML with less than 30% of blasts and IPSS 
scoring intermediate-2 or high. The diagnosis of MDS or 
AML was based on standard WHO criteria[23]. Patients 
(Pts) were to receive AZA at the FDA/EMEA approved 
schedule (75mg/m²/d, 7d/ 4 weeks). Pts having received ≥ 
1 cycle of AZA and who had bone marrow evaluation after 
≥ 4 cycles, or who died or progressed before completion 
of 4 cycles were considered evaluable (the last 2 groups 
were considered as treatment failures). Responses were 
scored according to IWG 2006 criteria for MDS and to 
Cheson et al.[24] for AML. Median number of AZA cycles 
at evaluation was 10 (3-22). All patients under treatment 
with AZA were included in protocol NCT01210274 
(www.clinicaltrials.gov). Informed consent was obtained 
for all patients. Cohort 2: 45 frozen samples from low-risk 
and high-risk MDS or AML patients were collected as part 
of an institutionally approved cellular sample collection 
protocol. Treatment of patients was the same as the one 
described for cohort 1.
Statistical analysis
BCL2L10 protein expression  in sensitive and 
resistant patients of both cohorts was studied by Student’s 
t-test. OS of patients from cohort 1 was measured from the 
date of BCL2L10 protein evaluation to either death from 
any cause or last follow-up. When patients were treated 
with consolidative allogeneic stem cell transplantation, 
the data were censored at the date of graft. Survival 
functions were estimated by the Kaplan-Meier method 
and compared by the log-rank test. Differences between 
the results of comparative tests were considered significant 
if the two-sided P value was less than 0.05. All statistical 
analyses were performed using SAS 9.13 (SAS Institute, 
Cary, NC).
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